400 Corporate Circle, Suite N
53 articles about PharmaJet
A systematic review and meta-analysis published in the April 30, 2021 issue of The Lancet strengthens evidence from previous publications that fractional dose delivery is a viable alternative to full dose inactivated polio vaccine.
PharmaJet ® , the maker of innovative, needle-free injection technology, announced that their latest research results will be presented at the World Vaccine Congress on May 6. The presentation, entitled Progress of COVID-19 Vaccines with Needle-Free Delivery , is being presented by Erin K. Spiegel, PhD, Vice President, Clinical & Regulatory Affairs
Feb. 9, 2021 13:08 UTC GOLDEN, Colo.--( BUSINESS WIRE )-- PharmaJet ® , the maker of innovative, needle-free injection technology, today announced that Marian Wentworth has been appointed to its Board of Directors. Ms. Wentworth, President and CEO of Management Sciences for Health, is an accomplished global health executive with extensive experience in global strategy, innovation, and development. Ron Lowy, Executive Chairman, PharmaJet Inc. said, “We are very pleased to we
PharmaJet ® , the maker of innovative, needle-free injection technology, today announced that its Tropis ® Needle-free Injection System will be used by Diomics , a San Diego-based biotech company, to deliver a biopolymer to detect the formation of an immune response to a SARS-CoV-2 protein. The company was awarded over $2 million by the Department
University of Cambridge Receives Multi-million Dollar Funding for Clinical Trial Using PharmaJet’s Needle-free System to Deliver Vaccine to Prevent COVID-19
PharmaJet ® , the maker of innovative, needle-free injection technology, today announced that its Needle-free Injection System will be used to deliver a vaccine against SARS-CoV-2 in a clinical trial. The vaccine developed by DIOSynVax , a spinoff company supported by the University of Cambridge in the UK, recently received multi-million dollar funding
PharmaJet ® , the maker of innovative, needle-free injection technology, today announced that Melissa Malhame, has joined the leadership team as Vice President, Business Development. Ms. Malhame is a global business executive with over 25 years of experience in business development, strategic sales, and marketing for major vaccin
PharmaJet and Abnova partner to develop and deliver COVID-19 mRNA Vaccine using Needle-free Injection technology
PharmaJet ® , the maker of innovative, needle-free injection technology, today announced that its Needle-free Injection System technology will be used to deliver a messenger RNA (mRNA) vaccine against SARS-CoV-2. The vaccine is being developed by Abnova Corporation , the world's largest antibody manufacturer, based in Taiwan . Abn
PharmaJet ® , the maker of innovative, needle-free injection technology, today announced the appointment of Chris Cappello to President and Chief Executive Officer. Chris replaces Ron Lowy , who was appointed Executive Chairman of the board. Ron Lowy , Executive Chairman, PharmaJet Inc. said, "In the 10 years that Chris h
PharmaJet ® , the maker of innovative, needle-free injection technology, today announced that its Tropis ® Needle-free injection system will be used to deliver a COVID-19 vaccine being developed by Immunomic Therapeutics, Inc . (ITI). ITI is a clinical stage biotechnology company pioneering the study of nucleic acid imm
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 10, 2020.
PharmaJet Received Multi-Year, Multi-Million Dollar Award to Support Next-Generation Needle-Free Delivery Devices
Technology being used to progress nucleic acid vaccines
Needle-free devices delivering superior immunogenicity
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that it is collaborating with PharmaJet, Inc., on the evaluation of PharmaJet’s needle-free injection system for administration of GeoVax’s Zika vaccine.
PharmaJet released positive interim results from the U.S. Army’s Phase I clinical trial of two hantavirus vaccines to prevent hemorrhagic fever with renal syndrome (HFRS).
Using needle-free device after significant increase in neutralizing antibody response in pre-clinical trials
PharmaJet®, the maker of innovative, needle-free injection technology, today announced a global license agreement with Genexine.
PharmaJet is expanding their human clinical trial for the study of a vaccine to treat HPV disease using the PharmaJet Stratis needle-free injection system.
PharmaJet announced that a study was published in Heliyon Journal showing PharmaJet needle-free injection is superior to needle and syringe for fractional dose poliovirus vaccine campaigns.
PharmaJet announced that a recently published study in The Lancet demonstrated that delivery of a Zika virus vaccine with the PharmaJet Stratis.
PharmaJet received US FDA approval to proceed with a phase II clinical trial of its therapeutic cancer vaccine, INVAC-1, using the PharmaJet needle-free injection system.